ТРОМБОЗ ЛЕВОГО ПРЕДСЕРДИЯ ПОСЛЕ УСТАНОВКИ ОККЛЮЗИРУЮЩЕГО УСТРОЙСТВА WATCHMAN DEVICE В УШКО ЛЕВОГО ПРЕДСЕРДИЯ

1. Мареев В. Ю., Агеев Ф. Т., Арутюнов Г. П., Коротеев А. В., Мареев Ю. В., Овчинников А. Г. и др. Национальные рекомендации ОССН, РКО и РНМОТ по диагностике и лечению ХСН (четвертый пересмотр). Сердечная недостаточность. 2013, 14, 7 (81).

2. Сулимов В. А., Голицын С. П., Панченко Е. П. и др. Диагностика и лечение фибрилляции предсердий. Рекомендации РКО, ВНОА и АССХ, 2012.

3. A John Camm (Chairperson) (UK), Gregory YH Lip (UK), Raffaele De Caterina (Italy), Irene Savelieva (UK), Dan Atar (Norway), Stefan H. Hohnloser (Germany), Gerhard Hindricks (Germany), Paulus Kirchhof (UK). 2012 focused update of the ESC Guidelinesfor the management of atrial brillation. European Heart Journal (2012) 33, 2719-2747 doi:10.1093/eurheartj/ehs253.

4. Lloyd-Jones DM, Wang TJ, Leip EP et al. Lifetime risk for development of atrial brillation: the Framingham Heart Study. Circulation 2004, 110: 1042-1046.

5. Stroke Risk in Atrial Fibrillation Working Group. Independent predictors of stroke in patients with atrial fibrillation: a systematic review. Neurology. 2007. 69: 546-554.

6. Stroke Risk in Atrial Fibrillation Working Group. Comparison of 12 risk stratification schemes to predict stroke in patients with nonvalvular atrial fibrillation. Stroke. 2008. 39: 1901-10.

7. Hart RG, Pearce LA, Aguilar MI. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann. Intern. Med. 146, 857-867 (2007).

8. You JJ, Singer DE, Howard PA et al.; American College of Chest Physicians. Antithrombotic therapy for atrial fibrillation: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence- Based Clinical Practice Guidelines. Chest 141 (2 Suppl.), 531-575.

9. Кропачева Е. С. Актуальные вопросы терапии Варфарином для практикующих врачей. Русский медицинский журнал, 2012, 14.

10. Levine MN, Raskob G, Landefeld S, Kearon C. Hemorrhagic complication of anticoagulant treatment Chest. 2001. 19 (1): 108-121.

11. Palareti G, Leali N, Coccheri S, Poggi M et al. Hemorrhagic complications of oral anticoagulant therapy: results of a prospective multicenter study ISCOAT (Italian Study on Complications of Oral Anticoagulant Therapy) G. Ital. Cardiol. 1997. 27 (3): 231-243.

12. Aung Myat, Yousif Ahmad, ShouvikHaldar, Udaya S Tantry, Simon R Redwood, Paul A Gurbel, Gregory YH Lip. The Inherent Risk of Antithrombotic Pharmacotherapy Used for Stroke Prevention in Atrial Fibrillation. Expert Rev CardiovascTher. 2013, 11 (8): 1029-1049.

13. Klein AL, Grimm RA, Murray RD, Apperson- Hansen C, Asinger RW, Black IW, Davidoff R, Erbel R, Halperin JL, Orsinelli DA, Porter TR, Stoddard MF. Use of transesophageal echocardiography to guide cardioversion in patients with atrial fibrillation. N Engl J Med. 2001 May 10, 344 (19): 1411-20.

14. Holmes D, Reddy VY, Turi Z et al. Percutaneous closure of the left atrial appendage versus warfarin therapy for prevention of stroke in patients with atrial fibrillation: a randomized non-inferiority trial. Lancet. 2009, 374: 534-542.

15. Reddy VY, Holmes D, Doshi SK, Neuzil P, Kar S. Safety of percutaneous left atrial appendage closure: results from the Watchman Left Atrial Appendage System for Embolic Protection in Patients with AF (PROTECT AF) clinical trial and the Continued Access Registry. Circulation. 2011 Feb 1, 123 (4): 417-24.